Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KOOL
CUSIPN/A
Phone916-858-5100
Debt
Debt-to-Equity Ratio0.23
Current Ratio1.61
Quick Ratio0.79
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.52 million
Price / Sales0.60
Cash FlowN/A
Price / CashN/A
Book Value$3.05 per share
Price / Book0.14
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net IncomeN/A
Net Margins-56.21%
Return on Equity-20.31%
Return on Assets-12.98%
Miscellaneous
Employees70
Outstanding Shares20,650,000
Market Cap$8.67
Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions
What is Cesca Therapeutics' stock symbol?
Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."
How were Cesca Therapeutics' earnings last quarter?
Cesca Therapeutics Inc (NASDAQ:KOOL) posted its earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) EPS for the quarter. The biotechnology company had revenue of $1.87 million for the quarter. Cesca Therapeutics had a negative return on equity of 20.31% and a negative net margin of 56.21%. View Cesca Therapeutics' Earnings History.
When is Cesca Therapeutics' next earnings date?
What price target have analysts set for KOOL?
1 equities research analysts have issued 1-year target prices for Cesca Therapeutics' shares. Their predictions range from $1.50 to $1.50. On average, they anticipate Cesca Therapeutics' share price to reach $1.50 in the next twelve months. This suggests a possible upside of 257.1% from the stock's current price. View Analyst Ratings for Cesca Therapeutics.
What is the consensus analysts' recommendation for Cesca Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Cesca Therapeutics' key competitors?
Some companies that are related to Cesca Therapeutics include Netscientific (NSCI), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), Hancock Jaffe Laboratories (HJLI), Akers Biosciences (AKER), PLx Pharma (PLXP), Biomerica (BMRA), Presbia (LENS), KITOV PHARMA LT/S (KTOV), SUMMIT THERAPEU/S (SMMT), Ceapro (CRPOF), ReNeuron Group (RNUGF), MRI Interventions (MRIC), Obalon Therapeutics (OBLN) and Acasti Pharma (ACST).
Who are Cesca Therapeutics' key executives?
Cesca Therapeutics' management team includes the folowing people:
- Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 45)
- Ms. Vivian H. Liu, COO, Corp. Sec. & Director (Age 56)
- Dr. Xiaochun Xu Ph.D., Chairman & CEO (Age 47)
- Mr. Joseph Balagot, Sr. VP of Corp. Devel.
- Dr. Venkatesh Ponemone Ph.D., F.A.C.G., Exec. Director of India Operations and Director of Clinical & Scientific Affairs (Age 42)
Has Cesca Therapeutics been receiving favorable news coverage?
News stories about KOOL stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cesca Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Cesca Therapeutics?
Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cesca Therapeutics' stock price today?
One share of KOOL stock can currently be purchased for approximately $0.42.
How big of a company is Cesca Therapeutics?
Cesca Therapeutics has a market capitalization of $8.67 million and generates $14.52 million in revenue each year. Cesca Therapeutics employs 70 workers across the globe.
How can I contact Cesca Therapeutics?
Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]
MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
